There is much to learn w.r.t. GLP-1s about the differences in outcomes between those who took compounded drugs versus patented versions, or both. For all the focus on AI in EMRs, getting clean data on this, combining both retailer/manufacturer data and individual purchase/medical record data would be a start. It's encouraging that pharma companies are investing in domestic API and manufacturing. Our dependence on overseas supplies is shocking, even more so for generic drugs (injectables and pills). The big question, I think, is whether we can produce the commodity chemicals domestically that make up much of API -- assuming labor cost differentials are the main barrier -- or have plans to create strategic stockpiles.
There is much to learn w.r.t. GLP-1s about the differences in outcomes between those who took compounded drugs versus patented versions, or both. For all the focus on AI in EMRs, getting clean data on this, combining both retailer/manufacturer data and individual purchase/medical record data would be a start. It's encouraging that pharma companies are investing in domestic API and manufacturing. Our dependence on overseas supplies is shocking, even more so for generic drugs (injectables and pills). The big question, I think, is whether we can produce the commodity chemicals domestically that make up much of API -- assuming labor cost differentials are the main barrier -- or have plans to create strategic stockpiles.